The CD40L–CD40 co-stimulatory interaction plays a significant role in the development of cardiovascular disease [1] and immunomodulation represents an attractive therapeutic target in cardiovascular disease [2]. This evidence concerns the gene CD40LG and cardiovascular disorder.